Fate Therapeutics FATE
NASDAQ FATE
$2.47 +0.05 (+2.07%)
As of: Sep 4, 2026 · 3:12 PM EDT

Fate Therapeutics (FATE) Non Operating Interest Expenses (2013 - 2019)

Analysis

Fate Therapeutics (FATE) Non Operating Interest Expenses (2013 - 2019) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Vertex Pharmaceuticals 138.58 Bn 130.73 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.33 Bn 77.33 Bn 3.93 Bn 11.00 Mn
3 Argenx Se 63.43 Bn 58.24 Bn 1.37 Bn -1.00 Mn
4 Moderna 57.84 Bn 52.70 Bn 52.00 Mn -
5 Revolution Medicines 44.01 Bn 44.01 Bn - 23.78 Mn
6 BeOne Medicines 39.93 Bn 34.83 Bn 1.53 Bn 39.74 Mn
7 Alnylam Pharmaceuticals 35.47 Bn 32.16 Bn 992.69 Mn 82.05 Mn
8 Royalty Pharma 28.39 Bn 27.56 Bn - 93.62 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 20.27 Mn
10 Fate Therapeutics 297.98 Mn 297.98 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2019 586,000.00
Sep 30, 2019 400,000.00
Jun 30, 2019 409,000.00
Mar 31, 2019 405,000.00
Dec 31, 2018 434,000.00
Sep 30, 2018 429,000.00
Jun 30, 2018 425,000.00
Mar 31, 2018 412,000.00
Dec 31, 2017 412,000.00
Sep 30, 2017 378,000.00
Jun 30, 2017 212,000.00
Mar 31, 2017 266,000.00
Dec 31, 2016 329,000.00
Sep 30, 2016 385,000.00
Jun 30, 2016 435,000.00
Mar 31, 2016 500,000.00
Dec 31, 2015 520,000.00
Sep 30, 2015 600,000.00
Jun 30, 2015 600,000.00
Mar 31, 2015 600,000.00